March 18, 2020
Lonza Manufacturing
Today, all Lonza Biosciences sites are operational, and we are producing and shipping customer orders as usual. All Lonza manufacturing sites are following applicable regulatory, safety and quality standards to ensure the safety of our employees and the products used by our life science customers around the globe.
Our teams are carefully monitoring and responding to the global development of COVID-19 and are in contact with various authorities around the world. Our response is aligned with pandemic guidance from global, national and local health authorities, including travel restrictions and guidance around self-isolation. We have increased hygiene, screening and social distancing measures at our sites in response to the COVID-19 outbreak.
Fresh Cell Availability
Some products in our fresh cell offering will be delayed. Our partner AllCells has temporarily suspended operations due to the March 16, 2020 mandatory shelter-in-place order in the San Francisco region of California. Shipments of Leukopaks and some other fresh blood and immune cells will be suspended until after April 7th, 2020.
We are still processing some fresh cell and bone marrow orders from our Lonza sites. However, to protect the safety of our donors, we plan to reduce or suspend collections, so it is important to check with our customer service team about availability before making your research plans. Most cryopreserved cells are on stock and available.